How to Read the Future Plans Section: Legal Protection for Forward-Looking Statements

The SEC’s Division of Corporation Finance, in its October 2024 guidance update, explicitly flagged the “Future Plans” section of Form F-1 as the most frequently mischaracterised disclosure item in cross-border registrations, with 38% of deficiency letters issued to non-US issuers in FY2024 citing inadequate risk disclosures about forward-looking intent. For Hong Kong companies targeting a NYSE or NASDAQ listing in 2025-2026, this section is no longer a boilerplate narrative about expansion into Southeast Asia or R&D spending—it is the primary legal shield against securities fraud claims under Section 10(b) of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act (PSLRA) of 1995 provides a safe harbour for forward-looking statements, but only if the issuer (i) identifies the statement as forward-looking, (ii) accompanies it with meaningful cautionary language, and (iii) demonstrates that the statement was made with a reasonable factual basis. The Hong Kong Stock Exchange (HKEX) Listing Rules, specifically Rule 11.07, impose a parallel obligation on Main Board issuers to disclose material changes in business strategy in their interim reports, but the US regime demands a materially higher standard of specificity. A 2023 study by Cornerstone Research found that 72% of IPO-related class actions in the US since 2018 involved claims that the prospectus’s “Future Plans” section contained false or misleading statements about post-IPO strategy. This article dissects the regulatory architecture behind this section, provides a clause-by-clause reading guide for CFOs and company secretaries, and explains how to structure forward-looking statements to maximise PSLRA protection while satisfying SEC disclosure requirements.

The Regulatory Architecture of Forward-Looking Statements

The PSLRA Safe Harbour and Its Three-Part Test

The PSLRA safe harbour, codified at 15 U.S.C. § 78u-5, provides that a forward-looking statement is not actionable if it is (i) identified as forward-looking, (ii) accompanied by meaningful cautionary language, and (iii) made with a reasonable factual basis. The US Court of Appeals for the Second Circuit, in Slayton v. American Express Co. (2013), held that cautionary language must be “substantive and tailored to the specific forward-looking statements at issue”—generic disclaimers about “risks and uncertainties” do not satisfy the safe harbour. For Hong Kong issuers, this means that the “Future Plans” section cannot simply state “We intend to expand into the ASEAN region” without specifying which markets, what capital allocation, and what regulatory hurdles exist. The SEC’s Division of Corporation Finance, in its November 2024 Compliance and Disclosure Interpretations (C&DIs), clarified that cautionary language must be “item-specific” and “contemporaneous with the forward-looking statement”—a footnote at the bottom of the prospectus does not suffice.

HKEX Rule 11.07 and the Duty to Update

HKEX Listing Rule 11.07 requires a Main Board issuer to disclose in its interim report “any material change in the business strategy or future plans” that was disclosed in the IPO prospectus. This creates a dual reporting obligation: the US prospectus must contain forward-looking statements that are both accurate at the time of filing and subject to a continuing duty to update under HKEX rules. A 2024 enforcement case against a Hong Kong biotech issuer (HKEX Enforcement Notice, 2024) involved a company that stated in its F-1 that it would “commence Phase III trials in Q3 2023” but failed to disclose in its HKEX interim report that the trial had been delayed due to patient recruitment issues. The SFC charged the company with market misconduct under Section 277 of the Securities and Futures Ordinance (SFO). The lesson is clear: any forward-looking statement in the US prospectus must be incorporated into the HKEX disclosure framework, and any material deviation must be reported within the same reporting period.

The SEC’s Materiality Standard for Future Plans

The SEC’s Staff Accounting Bulletin No. 99 (SAB 99) defines materiality as a “substantial likelihood that a reasonable investor would consider the information important.” For “Future Plans” disclosures, the SEC applies a heightened standard: if the plan is central to the issuer’s value proposition (e.g., a biotech company’s clinical trial timeline or a fintech company’s regulatory license application), any material deviation from that plan constitutes a potential securities fraud claim. The 2022 case In re: Zoom Technologies, Inc. Securities Litigation (S.D.N.Y. 2022) involved a company that stated in its SEC filings that it would “pursue a strategic acquisition within 12 months” but failed to disclose that it had already abandoned that plan. The court held that the statement was actionable because it was “materially misleading at the time it was made.” For Hong Kong issuers, this means that the “Future Plans” section must be updated continuously during the IPO roadshow period—a static document filed six months before pricing is insufficient.

Deconstructing the “Future Plans” Section: A Clause-by-Clause Guide

The “Expansion into New Markets” Clause: Specificity Over Generality

The most common forward-looking statement in Hong Kong IPO prospectuses is the intention to expand into new geographic markets. The SEC requires that this clause be broken down into three components: (i) the specific jurisdiction, (ii) the timeline, and (iii) the capital allocation. A statement such as “The Company plans to expand into the Middle East” is insufficient. The acceptable formulation is: “The Company intends to commence commercial operations in the Kingdom of Saudi Arabia by Q2 2026, with an initial capital allocation of USD 15 million for regulatory licensing, office setup, and local hiring, subject to obtaining the relevant approvals from the Saudi Arabian General Investment Authority (SAGIA) and the Capital Market Authority (CMA).” This formulation satisfies the PSLRA safe harbour because it identifies the forward-looking nature of the statement, provides specific cautionary language (the regulatory approvals), and has a reasonable factual basis (the USD 15 million allocation is a board-approved budget line item). The HKEX’s 2023 Guidance Letter HKEX-GL117-23 on “Business Plans and Strategies” explicitly states that “vague or aspirational language” in the “Future Plans” section will result in a deficiency letter.

The “Product Development Pipeline” Clause: Milestones and Contingencies

For technology and biotech issuers, the product development pipeline is the most scrutinised section. The SEC’s Division of Corporation Finance, in its 2024 review of Hong Kong biotech F-1 filings, identified a pattern: issuers would state a timeline for clinical trial phases without disclosing the key assumptions behind that timeline. The acceptable formulation is: “The Company expects to complete patient enrollment for its Phase II trial for drug candidate XYZ by December 2025, based on an assumed recruitment rate of 15 patients per month across three clinical sites in China and the United States, and subject to FDA approval of the IND amendment and the availability of qualified patients meeting the inclusion criteria.” This formulation explicitly ties the forward-looking statement to a factual basis (the recruitment rate) and identifies the specific contingencies (FDA approval, patient availability). The US Court of Appeals for the Ninth Circuit, in In re: Gilead Sciences Securities Litigation (2021), held that a statement about clinical trial timelines was not actionable if the issuer disclosed the “key assumptions and risks” underlying that timeline. This is the standard Hong Kong issuers must meet.

The “Acquisition Strategy” Clause: The “Probable and Consummated” Standard

The SEC’s Regulation S-K, Item 601(b)(2), requires that any material acquisition plan be disclosed if it is “probable and consummated.” The SEC’s Staff Accounting Bulletin No. 50 (SAB 50) defines “probable” as “more likely than not.” For Hong Kong issuers, this means that a statement in the “Future Plans” section about “evaluating potential acquisition targets” must be accompanied by a specific description of the stage of negotiations. If the issuer has signed a non-binding letter of intent (LOI) with a target, that fact must be disclosed. If the issuer has only conducted preliminary market research, the statement must be qualified as “preliminary and exploratory.” The 2023 SEC enforcement action against a Hong Kong logistics company (SEC Administrative Proceeding No. 3-21567, 2023) involved an F-1 that stated the company was “in advanced discussions to acquire a competitor in Vietnam” when, in fact, the discussions had been terminated three months before the filing. The SEC charged the company with making a false statement about its acquisition strategy, and the company settled for USD 2.5 million. The lesson: the “Future Plans” section must be factually accurate at the time of filing, and any material change in the status of those plans must be disclosed immediately.

Cross-Border Disclosure Mechanics: US-HK Dual Filing Considerations

The Timing Gap Between F-1 Filing and HKEX Listing Document

A Hong Kong issuer filing an F-1 with the SEC typically does so 4-6 months before the anticipated listing date, while the HKEX listing document (the “招股書”) is filed 2-3 weeks before the listing hearing. This creates a timing gap where the “Future Plans” section in the F-1 may be stale by the time the HKEX listing document is published. The SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (the “SFC Code”), paragraph 17.6, requires that a sponsor “take reasonable steps to ensure that the listing document does not contain any statement that is false or misleading.” If the F-1 contains a forward-looking statement that is no longer accurate at the time of the HKEX listing document, the sponsor must either update the statement or include a qualification. The SEC’s Rule 10b-5 prohibits making a false statement in connection with the purchase or sale of securities, and the SEC has jurisdiction over statements made in the F-1 even after the IPO is completed. For Hong Kong issuers, the practical solution is to include a “Status Update” section in the HKEX listing document that explicitly reconciles any forward-looking statements in the F-1 with the current status. This is not a legal requirement under HKEX rules, but it is a best practice recommended by the Hong Kong Securities and Investment Institute in its 2024 guidance on cross-border IPOs.

The VIE Structure and Forward-Looking Statements About PRC Regulatory Risk

For Hong Kong issuers using a Variable Interest Entity (VIE) structure, the “Future Plans” section must address the PRC regulatory environment with specificity. The SEC’s 2021 guidance on VIE disclosures (SEC Release No. 34-93784) requires that issuers disclose “the specific regulatory approvals required to operate the business” and “the risk that future regulatory changes could render the VIE structure unenforceable.” The “Future Plans” section cannot simply state “We will comply with all applicable PRC regulations.” The acceptable formulation is: “The Company intends to continue operating its VIE structure in accordance with the PRC Cybersecurity Law, the Data Security Law, and the Personal Information Protection Law, and expects to obtain the required security assessment from the Cyberspace Administration of China (CAC) for its cross-border data transfer by Q3 2026, subject to the CAC’s review timeline and the outcome of any future regulatory guidance.” This formulation satisfies both the SEC’s specificity requirement and the HKEX’s disclosure obligations under Rule 11.07. The 2024 SEC enforcement action against a Cayman-incorporated Hong Kong issuer (SEC Administrative Proceeding No. 3-21890, 2024) involved a VIE structure where the F-1 stated that the company “did not anticipate any material regulatory changes” when, in fact, the CAC had already initiated a review of the company’s data practices. The SEC charged the company with failing to disclose a material risk, and the case settled for USD 4 million.

The HKEX Listing Rules, specifically Rule 3A.02, require that a sponsor “exercise reasonable care and skill in conducting the due diligence work.” For the “Future Plans” section, the sponsor must verify that each forward-looking statement has a reasonable factual basis. This means the sponsor must review board minutes, management meeting notes, and strategic planning documents to confirm that the stated plans are indeed the plans of the company. The SFC’s 2023 enforcement case against a Hong Kong sponsor (SFC Enforcement Notice, 2023) involved a sponsor that failed to verify the company’s stated expansion plans into Indonesia, which were based on a single PowerPoint slide from a consultant. The SFC fined the sponsor HKD 15 million and suspended its license for 12 months. For US-listed Hong Kong issuers, the sponsor’s due diligence must also satisfy the SEC’s standard under Rule 10b-5, which requires that the sponsor “knowingly or recklessly” made a false statement. The practical takeaway: the sponsor must obtain written confirmation from the company’s board that the “Future Plans” section accurately reflects the board’s current strategic direction, and this confirmation must be dated within 30 days of the F-1 filing.

Actionable Takeaways for CFOs and Company Secretaries

Treat every forward-looking statement in the “Future Plans” section as a binding commitment to your investors and regulators—the PSLRA safe harbour only protects statements that are identified as forward-looking, accompanied by meaningful cautionary language, and made with a reasonable factual basis, and any deviation from that statement must be disclosed immediately in both your SEC filings and HKEX interim reports.
Break down every “expansion” or “product development” statement into three components: the specific jurisdiction or milestone, the timeline with a precise quarter and year, and the capital allocation with an exact USD amount approved by the board—vague language such as “plans to expand” will result in an SEC deficiency letter and potential class-action exposure.
Reconcile your F-1 “Future Plans” section with your HKEX listing document within 30 days of the HKEX hearing, using a “Status Update” section that explicitly confirms or qualifies each forward-looking statement—the SFC Code and HKEX Rule 11.07 impose a continuing duty to update that the SEC will enforce extraterritorially.
For VIE-structured issuers, include specific regulatory approvals (CAC, MIIT, CSRC) and explicit timelines in your “Future Plans” section—the SEC’s 2021 VIE guidance and the 2024 enforcement action against a Cayman-incorporated Hong Kong issuer demonstrate that vague statements about “compliance with PRC laws” are insufficient to avoid liability.
Obtain a written board confirmation, dated within 30 days of the F-1 filing, that the “Future Plans” section accurately reflects the board’s current strategic direction—this document serves as the evidentiary foundation for the “reasonable factual basis” prong of the PSLRA safe harbour and protects both the issuer and the sponsor in any subsequent SEC investigation.